The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).
 
Seth Andrew Wander
Consulting or Advisory Role - Foundation Medicine; InfiniteMD; Lilly; Puma Biotechnology
Research Funding - Genentech
 
Dejan Juric
No Relationships to Disclose
 
Jeffrey G. Supko
No Relationships to Disclose
 
Douglas Scott Micalizzi
No Relationships to Disclose
 
Laura Spring
Honoraria - Clinical Care Options; Dava Oncology
Consulting or Advisory Role - Lumicell; Novartis; Puma Biotechnology
Research Funding - Merck (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Merck; Tesaro
 
Neelima Vidula
Consulting or Advisory Role - Abbvie
Research Funding - DAEHWA Pharmaceutical (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst)
 
Maureen Beeler
No Relationships to Disclose
 
Karleen R. Habin
No Relationships to Disclose
 
Elene Viscosi
No Relationships to Disclose
 
Donna Michelle Fitzgerald
No Relationships to Disclose
 
Lauren Scarpetti
No Relationships to Disclose
 
Elizabeth Tripp
No Relationships to Disclose
 
Rachel Hepp
No Relationships to Disclose
 
Beverly Moy
Consulting or Advisory Role - Dark Canyon Labs (I); MOTUS (I); Remedy Partners (I)
Research Funding - Puma Biotechnology (Inst)
 
Steven J. Isakoff
Consulting or Advisory Role - Abbvie; Hengrui Therapeutics; Immunomedics; Mylan; Myriad Genetics; OncoPep; OncoPep; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst); PharmaMar (Inst)
 
Leif W. Ellisen
Honoraria - Invitae
Travel, Accommodations, Expenses - Invitae
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - bioTheranostics